RxDoctor Payments Data

Courtney Parr

Nurse Practitioner · Rome, GANPI 1205522158

Payments from drug & device makers

$1,050in general payments, 2019–2025

Across 47 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$209
  • Cvrx, Inc.$182
  • Novartis$128
  • AstraZeneca$100
  • Lexicon Pharmaceuticals, Inc.$97
  • Amgen$62
  • plus $270 from 11 others

What the payments were for

  • Food & beverage$1,050100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,050 in reported general payments places this provider in the 75th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$21,766
Medicare patients
187
Services billed
299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban129$139,365
CamzyosMavacamten12$100,034
XareltoRivaroxaban47$56,351
JardianceEmpagliflozin44$45,601
EntrestoSacubitril/Valsartan25$31,178
Repatha SureclickEvolocumab20$14,653
Repatha SyringeEvolocumab14$7,829
Ranolazine ErRanolazine33$2,604
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$1,555
Atorvastatin Calcium145$1,099
Metoprolol Tartrate216$1,077
Metoprolol Succinate78$969
Nebivolol Hcl13$769
Losartan Potassium70$713
Hydralazine Hcl36$617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$209$100,03412 claims
Johnson & JohnsonXarelto$34$56,35147 claims
Boehringer IngelheimJardiance$18$45,60144 claims
NovartisEntresto$128$31,17825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →